Stock Evaluator: Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. RARE

$17.73 1.03 6.17%
November 18, 2026 4:00:00 PM EST November 10, 2021 Volume: 5,163,344
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Commentary & Analysis


Financial Summary

Share Statistics RARE Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,696.1 $208.2 53%
Shares Out (Mil) 102.1 55.4 62%
Institutional Ownership 96.6% 92.9% 70%
Float (Mil) 77.4 40.7 55%
Beta 0.36 1.00 19%
Avg Daily Volume (000s) 4,390 570 90%
Price Change
(52-week)
(49.6%) 40.7% 21%
Growth RARE Industry
Median
Percentile
(All Stocks)
Sales (5yr) 20.0% 13.2% 81%
Net Income (5yr) (25.2%) (10.3%) 17%
EPS (5yr) (13.7%) 15.5% 19
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (11.7%) (15.7%) 57%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 6 6 6
Current EPS $0.655 ($3.049) $1.433
Month Ago EPS ($0.662) ($4.078) $0.226
# Rev Up 0 0 1
# Rev Down 1 1 0
Three Months Ago EPS ($0.074) ($2.564) $2.634
Year/Year Chg (156.7%) (47.7%) (121.4%)
Financials RARE Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $730 $39 45%
Net Income (TTM) (Mil) ($524) ($44) 2%
EPS (TTM) ($5.180) ($1.400) 7%
Operating Cash Flow (TTM) (Mil) ($437) ($34) 2%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $1,106 $4 67%
Enterprise Value (Q1) (Mil) $2,374 $138 52%
Valuation RARE Industry
Median
Percentile
(All Stocks)
P/B na 1.96 na
P/E na 17.7 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.8 na
Ratios RARE Industry
Median
Percentile
(All Stocks)
Gross Margin (10.7%) 67.9% 3%
Net Margin (71.8%) (50.8%) 9%
ROA (44.1%) (47.4%) 12%
ROE 285.7% (51.6%) 99%
Liabilities to Assets 131.1% 29.7% 98%
F-Score 3 3 18%

Ultragenyx Pharmaceutical Inc. did not pass any screens on 11/17/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors